Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 11/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.39 |
| ▸ | KLK1 | P06870 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22895913 | 0.84 | F10 (0.41) | F10CAPN1KLKB1KLK1TACR1 | |
| SCHEMBL22896504 | 0.84 | F10 (0.43) | F10CAPN1KLKB1KLK1TACR1 | |
| SCHEMBL22896661 | 0.84 | CAPN1 (0.43) | F10CAPN1KLKB1KLK1TACR1 | |
| SCHEMBL22896361 | 0.84 | ITGB2 (0.47) | TACR1CTSL | |
| SCHEMBL22895897 | 0.84 | PSMB5 (0.41) | CAPN1 | |
| SCHEMBL22896292 | 0.84 | CAPN1 (0.50) | CAPN1CTSS | |
| SCHEMBL22896420 | 0.84 | HDAC6 (0.41) | CAPN1CTSSCTSK | |
| SCHEMBL22896797 | 0.83 | F10 (0.43) | F10CAPN1KLKB1KLK1TACR1 | |
| SCHEMBL22896158 | 0.82 | USP30 (0.40) | CAPN1CTSSSMN1; SMN2 | |
| SCHEMBL22896493 | 0.82 | CAPN1 (0.44) | CAPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | F10 4552/4885CAPN1 3/4885KLKB1 3617/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | F10 4424/4885CAPN1 4/4885KLKB1 3602/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | F10 4552/4885CAPN1 3/4885KLKB1 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.